Axovant Reports Financial Results for the First Fiscal Quarter of 2015 and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- Wall St futures mixed ahead of CPI, bank earnings; US-Iran tensions in focus
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Axovant Sciences Ltd. (AXON) Reports Q1 Loss of $0.35, Names CFO
August 11, 2015 4:24 PM EDTAxovant Sciences Ltd. (NYSE: AXON) reported Q1 EPS of ($0.35).
"We remain on track to commence the confirmatory phase 3 study for RVT-101 in Alzheimer's disease in the fourth quarter of 2015," stated Vivek Ramaswamy, Chief Executive Officer of Axovant Sciences, Inc. "We look forward to providing additional updates later this year regarding our progress towards building a dementia solutions company."
Leadership Update
Axovant is pleased to announce the appointment of Gregory Weinhoff, MD, MBA as the Chief Financial Officer... More
